{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:55Z","timestamp":1790375995953,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.humpath.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T04:54:03Z","timestamp":1459659243000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas"],"prefix":"10.1016","volume":"54","author":[{"given":"Thomas","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bodmer-Haecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Dirnhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.03.005_bb0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0010","first-page":"17","article-title":"Role of PD-1 in regulating T-cell immunity","volume":"350","author":"Jin","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.humpath.2016.03.005_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.humpath.2016.03.005_bb0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2014preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD-1\/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy","volume":"19","author":"Muenst","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.humpath.2016.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"key":"10.1016\/j.humpath.2016.03.005_bb0045","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.humpath.2016.03.005_bb0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5858\/2009-0463-RSR.1","article-title":"Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma","volume":"135","author":"Hutchinson","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2016.03.005_bb0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3109\/10428194.2012.733881","article-title":"Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2016.03.005_bb0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.humpath.2016.03.005_bb0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.humpath.2016.03.005_bb0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.03.005_bb0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non\u2013small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.03.005_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2016.03.005_bb0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2008.207","article-title":"Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas","volume":"22","author":"Meier","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0095","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1309\/AJCP77KMKJXNMPMS","article-title":"Tissue-sparing application of the newly proposed IASLC\/ATS\/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact","volume":"137","author":"Sterlacci","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0100","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.03.005_bb0105","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.03.005_bb0110","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-014-3061-0","article-title":"Unvalidated antibodies and misleading results","volume":"147","author":"Rimm","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2016.03.005_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.humpath.2016.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood.V87.4.1571.bloodjournal8741571","article-title":"Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene","volume":"87","author":"Joos","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2016.03.005_bb0135","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2016.03.005_bb0140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.03.005_bb0145","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2016.03.005_bb0150","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2009-02-204842","article-title":"Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma","volume":"114","author":"Navarro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2016.03.005_bb0155","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CCO.0000000000000212","article-title":"Targeting the programmed death-1\/programmed death-ligand 1 axis in lymphoma","volume":"27","author":"Cheah","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0170","doi-asserted-by":"crossref","first-page":"e1002729","DOI":"10.1080\/2162402X.2014.1002729","article-title":"PDL1 expression is an independent prognostic factor in localized GIST","volume":"4","author":"Bertucci","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.humpath.2016.03.005_bb0175","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2016.03.005_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2407-8-57","article-title":"FOXP3+ Tregs and B7-H1+\/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy","volume":"8","author":"Ghebeh","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2016.03.005_bb0185","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.4049\/jimmunol.180.4.2069","article-title":"pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules","volume":"180","author":"Singh","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000321567","article-title":"Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma","volume":"77","author":"Tzankov","year":"2010","journal-title":"Pathobiology"},{"key":"10.1016\/j.humpath.2016.03.005_bb0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PAI.0000000000000107","article-title":"Diagnostic utility of the germinal center-associated markers GCET1, HGAL, and LMO2 in hematolymphoid neoplasms","volume":"23","author":"Menter","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2016.03.005_bb0205","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/01.MP.0000071843.09960.BF","article-title":"Longer failure-free survival interval of Epstein-Barr virus\u2013associated classical Hodgkin's lymphoma: a single-institution study","volume":"16","author":"Krugmann","year":"2003","journal-title":"Mod Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716300144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716300144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:35:46Z","timestamp":1655422546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716300144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":41,"alternative-id":["S0046817716300144"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.03.005","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}